Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001069918 | SCV001235116 | uncertain significance | Ehlers-Danlos syndrome, dermatosparaxis type | 2022-07-30 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 1113 of the ADAMTS2 protein (p.His1113Tyr). This variant is present in population databases (rs372096858, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with ADAMTS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 863049). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV004794486 | SCV005415374 | uncertain significance | not provided | 2024-05-21 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV001069918 | SCV002081887 | uncertain significance | Ehlers-Danlos syndrome, dermatosparaxis type | 2020-11-23 | no assertion criteria provided | clinical testing |